Sunshine Biopharma, Inc. (SBFM)Healthcare | Drug Manufacturers - Specialty & Generic | Fort Lauderdale, United States | NasdaqCM
1.03 USD
-0.01
(-1.338%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:19 a.m. EDT
SBFM is a high-risk speculative vehicle with deteriorating fundamentals (10% revenue decline, negative operating cash flow) obscured by bullish analyst targets ($5.60) likely driven by a reverse-split expectation. The recent price action shows choppy weakness with no clear upward momentum, and the company has no dividend history, making it unsuitable for conservative investments. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.067393 |
| AutoETS | 0.071688 |
| AutoTheta | 0.119477 |
| AutoARIMA | 0.160364 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 11.89 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.317 |
| Excess Kurtosis | -0.94 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.526 |
| Revenue per Share | 8.733 |
| Market Cap | 5,028,594 |
| Forward P/E | 0.01 |
| Beta | 1.60 |
| Profit Margins | -16.46% |
| Website | https://sunshinebiopharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.24074072 |
| Address1 | 333 Las Olas Way |
| Address2 | CU4 Suite 433 |
| All Time High | 19,740.0 |
| All Time Low | 0.953 |
| Ask | 1.31 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 33,530 |
| Average Daily Volume3 Month | 36,245 |
| Average Volume | 36,245 |
| Average Volume10Days | 33,530 |
| Beta | 1.602 |
| Bid | 0.7272 |
| Bid Size | 2 |
| Book Value | 4.693 |
| City | Fort Lauderdale |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.025 |
| Current Ratio | 4.167 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.03 |
| Day Low | 1.0102 |
| Debt To Equity | 3.526 |
| Display Name | Sunshine Biopharma |
| Dividend Date | 1,586,131,200 |
| Earnings Timestamp End | 1,755,547,200 |
| Earnings Timestamp Start | 1,755,201,600 |
| Ebitda | -4,146,712 |
| Ebitda Margins | -0.11422 |
| Enterprise To Ebitda | 0.788 |
| Enterprise To Revenue | -0.09 |
| Enterprise Value | -3,269,292 |
| Eps Forward | 199.8 |
| Eps Trailing Twelve Months | -1.44 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.1025 |
| Fifty Day Average Change | -0.077499986 |
| Fifty Day Average Change Percent | -0.070294775 |
| Fifty Two Week Change Percent | -24.074072 |
| Fifty Two Week High | 2.43 |
| Fifty Two Week High Change | -1.4050001 |
| Fifty Two Week High Change Percent | -0.5781893 |
| Fifty Two Week Low | 0.953 |
| Fifty Two Week Low Change | 0.07199997 |
| Fifty Two Week Low Change Percent | 0.075550854 |
| Fifty Two Week Range | 0.953 - 2.43 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,644,935,400,000 |
| Float Shares | 4,803,950 |
| Forward Eps | 199.8 |
| Forward P E | 0.00513013 |
| Free Cashflow | -4,632,801 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 50 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.33757 |
| Gross Profits | 12,255,677 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00041 |
| Held Percent Institutions | 0.05244 |
| Implied Shares Outstanding | 4,905,946 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ipo Expected Date | 2,022-02-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,723,075,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida. |
| Long Name | Sunshine Biopharma, Inc. |
| Market | us_market |
| Market Cap | 5,028,594 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_78729055 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -5,975,352 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,028,593 |
| Number Of Analyst Opinions | 1 |
| Open | 1.03 |
| Operating Cashflow | -5,331,073 |
| Operating Margins | -0.19333 |
| Payout Ratio | 0.0 |
| Phone | 954 330 0684 |
| Pre Market Change | 0.024999976 |
| Pre Market Change Percent | 2.439022 |
| Pre Market Price | 1.05 |
| Pre Market Time | 1,776,773,336 |
| Previous Close | 1.0389 |
| Price Hint | 4 |
| Price To Book | 0.2184104 |
| Price To Sales Trailing12 Months | 0.13850628 |
| Profit Margins | -0.16458 |
| Quick Ratio | 1.953 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.013900042 |
| Regular Market Change Percent | -1.3379576 |
| Regular Market Day High | 1.03 |
| Regular Market Day Low | 1.0102 |
| Regular Market Day Range | 1.0102 - 1.03 |
| Regular Market Open | 1.03 |
| Regular Market Previous Close | 1.0389 |
| Regular Market Price | 1.025 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 14,291 |
| Return On Assets | -0.09232 |
| Return On Equity | -0.25679 |
| Revenue Growth | -0.106 |
| Revenue Per Share | 8.733 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,905,945 |
| Shares Percent Shares Out | 0.028499998 |
| Shares Short | 140,026 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 225,823 |
| Short Name | Sunshine Biopharma Inc. |
| Short Percent Of Float | 0.0286 |
| Short Ratio | 3.94 |
| Source Interval | 15 |
| State | FL |
| Symbol | SBFM |
| Target High Price | 5.6 |
| Target Low Price | 5.6 |
| Target Mean Price | 5.6 |
| Target Median Price | 5.6 |
| Total Cash | 9,123,308 |
| Total Cash Per Share | 1.86 |
| Total Debt | 812,422 |
| Total Revenue | 36,305,892 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.391445 |
| Two Hundred Day Average Change | -0.36644506 |
| Two Hundred Day Average Change Percent | -0.26335576 |
| Type Disp | Equity |
| Volume | 14,291 |
| Website | https://sunshinebiopharma.com |
| Zip | 33,301 |